Vandana Singh
·
July 14, 2025
Benzinga
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.
read more
September 19, 2025
September 5, 2025
August 20, 2025
Fortune
August 13, 2025
August 26, 2025
Bloomberg